ScienceNew Pancreatic Cancer Pill Nearly Doubles Survival in 500-Patient Trial
A once-daily pill called daraxonrasib pushed median survival from 6.7 to 13.2 months in advanced pancreatic cancer — the first real breakthrough in a disease long called "undruggable."
